Healthy Clinical Trial
Official title:
Mobile Health Biometrics to Enhance Exercise and Physical Activity Adherence
| Verified date | August 2022 |
| Source | Liverpool John Moores University |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
The investigators aim to undertake a feasibility randomised controlled trial (RCT) to investigate whether mHealth technology, allowing biometric informed feedback and coaching on exercise and PA, can be effective in previously sedentary individuals. The overall objective is to have an evidence-based exercise and PA intervention ready to evaluate in a future RCT.
| Status | Completed |
| Enrollment | 86 |
| Est. completion date | July 1, 2022 |
| Est. primary completion date | April 1, 2022 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | All |
| Age group | 18 Years to 75 Years |
| Eligibility | Inclusion Criteria: - Male or female - Aged 18-75 - No known cardiovascular or metabolic disorder (e.g. heart failure, diabetes, previous myocardial infarction etc.) - Able to exercise safely as deemed by completion of the PAR-Q+. - Not currently meeting the recommended exercise guidelines (150 minutes moderate or 75 minutes of vigorous intensity physical activity per week), as assessed during screening questions related to the participants previous activity levels. Exclusion Criteria: - Aged <18 or >75 - Pregnancy or planning to become pregnant in the next 3 months - <6 months postpartum or stopped breastfeeding <1 month before recruitment - Not owning a smartphone with a data plan or access to WiFi |
| Country | Name | City | State |
|---|---|---|---|
| United Kingdom | Liverpool John Moores University | Liverpool |
| Lead Sponsor | Collaborator |
|---|---|
| Liverpool John Moores University |
United Kingdom,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Device derived adherence to structured exercise | Number of exercise sessions per week | Through study completion, an average 12 weeks | |
| Primary | Device derived duration to structured exercise | minutes of exercise completed per session | Through study completion, an average 12 weeks | |
| Primary | Device derived intensity of structured exercise | intensity of exercise sessions performed (% of HR max) | Through study completion, an average 12 weeks | |
| Primary | Change in Device derived physical activity (GENEActiv) | minutes of Moderate and Vigorous physical activity | Baseline, Mid intervention (Week 6-7), the final 2 weeks of intervention period (weeks 10-12). | |
| Primary | Change in Survey reported exercise behaviour (Godin Leisure Time Exercise Questionnaire (GLTEQ)) | Bouts of mild, moderate and strenuous exercise lasting =30 minutes | Baseline, 4, 6, 8 12 weeks | |
| Secondary | Height | Height (m) | Baseline, 6-weeks and immediately following intervention (12 weeks) | |
| Secondary | Weight | Weight (kg) | Baseline, 6-weeks and immediately following intervention (12 weeks) | |
| Secondary | Waist Circumference | Waist Circumference (cm) | Baseline, 6-weeks and immediately following intervention (12 weeks) | |
| Secondary | Concentration of Hba1c | Hba1c | Baseline and immediately following intervention (12 weeks) | |
| Secondary | Blood Lipid concentrations | Total cholesterol, HDL/LDL, Triglycerides | Baseline and immediately following intervention (12 weeks) | |
| Secondary | Glycaemic control | Flash glucose monitoring | Baseline and immediately following intervention (12 weeks) | |
| Secondary | Patient qualitative survey on intervention acceptability | Study specific questionnaire (qualitative data) | Immediately following intervention (12 weeks) | |
| Secondary | Patient qualitative survey on testing acceptability | Study specific questionnaire (qualitative data) | 7 Days following baseline testing | |
| Secondary | Exercise motivation | Behavioural regulation in exercise questionnaire-2 (BREQ-2). Max score 76, min score 0, high score is better | Baseline, Mid (week 6) and post (week 12) | |
| Secondary | 12-Item Short Form Survey | SF-12 Questionnaire (max 44 min 8, high score mean better outcome) | Baseline, Mid (week 6) and post (week 12) | |
| Secondary | Patient Interview to access intervention acceptability | Patient interview | Within 2 weeks of the end of the intervention | |
| Secondary | Patient Interview to access testing acceptability | Patient interview | Within 2 weeks of the baseline testing |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06052553 -
A Study of TopSpin360 Training Device
|
N/A | |
| Completed |
NCT05511077 -
Biomarkers of Oat Product Intake: The BiOAT Marker Study
|
N/A | |
| Recruiting |
NCT04632485 -
Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
|
||
| Completed |
NCT05931237 -
Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults
|
N/A | |
| Completed |
NCT04527718 -
Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers
|
Phase 1 | |
| Terminated |
NCT04556032 -
Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women
|
N/A | |
| Completed |
NCT04065295 -
A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225
|
Phase 1 | |
| Completed |
NCT04998695 -
Health Effects of Consuming Olive Pomace Oil
|
N/A | |
| Completed |
NCT04107441 -
AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects
|
Phase 1 | |
| Completed |
NCT01442831 -
Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects
|
Phase 1 | |
| Terminated |
NCT05934942 -
A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood
|
Phase 1 | |
| Recruiting |
NCT05525845 -
Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI
|
N/A | |
| Completed |
NCT05515328 -
A Study in Healthy Men to Test How BI 685509 is Processed in the Body
|
Phase 1 | |
| Completed |
NCT05030857 -
Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects
|
Phase 1 | |
| Completed |
NCT04967157 -
Cognitive Effects of Citicoline on Attention in Healthy Men and Women
|
N/A | |
| Recruiting |
NCT04714294 -
Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers
|
Phase 1 | |
| Recruiting |
NCT04494269 -
A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls
|
Phase 1 | |
| Completed |
NCT04539756 -
Writing Activities and Emotions
|
N/A | |
| Recruiting |
NCT04098510 -
Concentration of MitoQ in Human Skeletal Muscle
|
N/A | |
| Completed |
NCT03308110 -
Bioavailability and Food Effect Study of Two Formulations of PF-06650833
|
Phase 1 |